Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein, which along with SMARCA4 controls gene regulation through chromatin remodeling, which is in phase 1 clinical trial for the treatment of advanced or metastatic solid tumors; PRT7732, selective and orally bioavailable SMARCA2 degraders, which is in phase 1 multi-dose escalation trial for the treatment of advanced or metastatic solid tumors and; PRT2527, a Cyclin-dependent Kinase 9 inhibitor, which is in phase 1 dose-escalation and confirmation for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Prelude Therapeutics Incorporated

The latest announcement is out from Prelude Therapeutics ( ($PRLD) ). On September 10, 2026, Prelude Therapeutics announced that the U.S. Food and ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRLD	$3.98	-7.66%	310.28K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRLD	$3.98	-7.7%	310.28K
3
4
5
6

PRLD

Get Prelude Therapeutics Incorporated Data in Excel

Get Prelude Therapeutics Incorporated Data in Excel